-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Encorafenib in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Encorafenib in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Encorafenib in Relapsed Multiple Myeloma Drug Details: Encorafenib (Braftovi) acts as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navitoclax Dihydrochloride in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Navitoclax Dihydrochloride in Myelofibrosis Drug Details: Navitoclax (ABT-263, RG7433) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-442257 in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SAR-442257 in Refractory Multiple Myeloma Drug Details: SAR-442257 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – XW-014
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry XW-014 Drug Details XW-014 is under development for the treatment of non-alcoholic steatohepatitis (NASH),...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – XW-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry XW-001 Drug Details XW-001 is under development for the treatment of coronavirus disease 2019...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ecnoglutide
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ecnoglutide Drug Details XW-003 is under development for the treatment of non-alcoholic steatohepatitis (NASH),...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – XW-004
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry XW-004 Drug Details XW-004 is under development for the treatment of nonalcoholic steatohepatitis (NASH),...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Respiratory syncytial virus (RSV) infection infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The Respiratory Syncytial Virus pipeline market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological...